Discovery and Development of Novel Ret Inhibitors for the Treatment of Pervasive Malignancies
Targeted cancer therapeutics represent the advent of a new therapeutic age, brought forth by the small molecule tyrosine kinase inhibitor (TKI) imatinib (Gleevec®). Imatinib is able to cause complete and sustained remissions in patients with chronic myelogenous leukemia (CML) driven by the Abelson...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
The University of Arizona.
2014
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10150/325495 |